Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine ('foxy') to adult rats: A new drug of abuse

Neuropsychopharmacology

Volumn 32, Issue 6, 2007, Pages 1404-1420

  Williams, Michael T ^a,c   Herring, Nicole R ^a   Schaefer, Tori L ^a   Skelton, Matthew R ^a   Campbell, Nicholas G ^a   Lipton, Jack W ^a   McCrea, Anne E ^b   Vorhees, Charles V ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b SINCLAIR COMMUNITY COLLEGE   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Cincinnati water maze; Morris water maze; Path integration; Spatial learning; Spontaneous locomotion

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 METHOXYDIISOPROPYLTRYPTAMINE; CORTICOSTERONE; ILLICIT DRUG; MONOAMINE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; COGNITION; DATA ANALYSIS; ENDOCRINE SYSTEM; HYPERTHERMIA; LOCOMOTION; MALE; MAZE TEST; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; TEMPERATURE MEASUREMENT;

5-METHOXYTRYPTAMINE; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; BODY TEMPERATURE; BODY WEIGHT; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; CORTICOSTERONE; DATA INTERPRETATION, STATISTICAL; DESIGNER DRUGS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; METHAMPHETAMINE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; SWIMMING;

EID: 34249041296     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301232     Document Type: Article

References (71)

1. Able JA, Gudelsky GA, Vorhees CV, Williams MT (2006). 3,4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory. Biol Psychiatry 59: 1219-1226.
2. Akana SF, Shinsako J, Dallman MF (1983). Drug-induced adrenal hypertrophy provides evidence for reset in the adrenocortical system. Endocrinology 113: 2232-2237.
3. Alatrash G, Majhail NS, Pile JC (2006). Rhabdomyolysis after ingestion of 'foxy,' a hallucinogenic tryptamine derivative. Mayo Clin Proc 81: 550-551.
4. Alyan S, McNaughton BL (1999). Hippocampectomized rats are capable of homing by path integration. Behav Neurosci 113: 19-31.
5. Bakker JM, Kavelaars A, Heijnen CJ, Tilders FJH, van Rees EP (1997). Effects of neonatal dexamethasone treatment on hypothalamo-pituitary-adrenal axis and immune system of the rat. J Neuroimmunol 74: 69-76.
6. Balcombe JP, Barnard ND, Sandusky C (2004). Laboratory routines cause animal stress. Contemp Top Lab Anim Sci 43: 42-51.
7. Belcher AM, O'Dell SJ, Marshall JF (2005). Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine-or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 30: 2026-2034.
8. Bisagno V, Ferguson D, Luine VN (2002). Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res 940: 95-101.
9. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker Jr W et al (1994). Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Therap 268: 1571-1580.
10. Cappon G, Morford LL, Vorhees CV (1997). Ontogeny of methamphetamine- induced neurotoxicity and associated hyperthermic response. Dev Brain Res 103: 155-162.
11. Cho AK (1990). Ice: a new dosage form of an old drug. Science 249: 631-634.
12. Cho AK, Melega WP, Kuczenski R, Segal DS (2001). Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39: 161-166.
13. Clark RE, Zola SM, Squire LR (2000). Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20: 8853-8860.
14. Cohen MA, Skelton MR, Schaefer TL, Gudelsky GA, Vorhees CV, Williams MT (2005). Learning and memory after neonatal exposure to 3,4- methylenedioxymethamphetamine (ecstasy) in rats: interaction with exposure in adulthood. Synapse 57: 148-159.
15. Derlet RW, Heischober B (1990). Methamphetamine: stimulant of the 1990s? West J Med 153: 625-628.
16. Drug Enforcement Administration (DEA) DoJ (2004). Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N- diisopropyltryptamine into schedule I of the controlled substances act. Final rule Federal Register 69: 58050-58053.
17. Eckler JR, Chang-Fong J, Rabin RA, Smith C, Teitler M, Glennon RA et al (2003). Behavioral characterization of 2-O-desmethyl and 5-O-desmethyl metabolites of the phenylethylamine hallucinogen DOM. Pharmacol Biochem Behav 75: 845-852.
18. EMCDDA (2004). Annual Report 2004: The state of the drugs problem in the European Union and Norway, European Monitoring Centre for Drugs and Drug Addiction, Luxembourg.
19. Etienne AS, Jeffery KJ (2004). Path integration in mammals. Hippocampus 14: 180-192.
20. Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC et al (2006). Hallucinogen-like actions of 5-methoxy-N,N- diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83: 122-129.
21. Farfel GM, Seiden LS (1995). Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J Pharmacol Exp Therap 272: 868-875.
22. Friedman SD, Castaneda E, Hodge GK (1998). Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61: 35-44.
23. Gleason SD, Lucaites VL, Shannon HE, Nelson DL, Leander JD (2001). m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors. Behav Pharmacol 12: 613-620.
24. Glennon RA, Young R, Jacyno JM, Slusher M, Rosecrans JA (1983). DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol 86: 453-459.
25. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508.
26. Hanson GR, Jensen M, Johnson M, White HS (1999). Distinct features of seizures induced by cocaine and amphetamine analogs. Eur J Pharmacol 377: 167-173.
27. Hanson GR, Rau KS, Fleckenstein AE (2004). The methamphetamine experience: a NIDA partnership. Neuropharmacology 47(Suppl 1): 92-100.
28. Hoh TE, Kolb B, Eppel A, Vanderwolf CH, Cain DP (2003). Role of the neocortex in the water maze task in the rat: a detailed behavioral and Golgi-Cox analysis. Behav Brain Res 138: 81-94.
29. Ikeda A, Sekiguchi K, Fujita K, Yamadera H, Koga Y (2005). 5-methoxy-n,n-diisopropyltryptamine-induced flashbacks. Am J Psychiatry 162: 815.
30. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2004). Monitoring the Future National Survey Results on Drug Abuse, 1975-2003. Vol. II College Students and Adult Ages 19-45 (NIH Publication No. 04-5508). National Institute on Drug Abuse: Bethesda, MD.
31. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2005). Monitoring the Future National Survey Results on Drug Abuse, 1975-2004. Vol. I Secondary School Students (NIH Publication No. 05-5727). National Institute on Drug Abuse: Bethesda, MD.
32. Kioukia-Fougia N, Antoniou K, Bekris S, Liapi C, Christofidis I, Padadopoulou-Daifoti Z (2002). The effects of stress exposure on the hypothalamic-pituitary-adrenal axis, thymus, thyroid hormones and glucose levels. Prog Neuropsychopharmacol Biol Psychiatry 26: 823-830.
33. Kirk RE (1995). Experimental Design: Procedures for the Behavioral Sciences. Brooks/Cole Publishing Co: Pacific Grove.
34. Kiyota K (2004). Latest cases of acute poisoning in clinical practice - 5MeO-DIPT and GHB precursor. Chudoku Kenkyu 17: 259-266.
35. Koprich JB, Campbell NG, Lipton JW (2003). Neonatal 3,4- methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. Brain Res Dev Brain Res 147: 177-182.
36. Kouimtsidis C, Schifano F, Sharp T, Ford L, Robinson J, Magee C (2006). Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets. Psychosomatics 47: 86-87.
37. Lin JH (1998). Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 26: 1202-1212.
38. Lindner MD (1997). Reliability, distribution, and validity of agerelated cognitive deficits in the Morris water maze. Neurobiol Learn Mem 68: 203-220.
39. Mahmood I (1999). Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. J Pharm Pharmacol 51: 905-910.
40. Meatherall R, Sharma P (2003). Foxy, a designer tryptamine hallucinogen. J Anal Toxicol 27: 313-317.
41. Miller DB, O'Callaghan JP (1995). The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol 11: 177-192.
42. Mordenti J, Chappell W (1989). The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V (eds). Toxicokinetics in New Drug Development. Pergamon Press: New York. pp. 42-96.
43. Morimoto M, Morita N, Ozawa H, Yokoyama K, Kawata M (1996). Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical and in situ hybridization study. Neurosci Res 26: 235-269.
44. Morris RGM, Garrud P, Rawlins JNP, O'Keefe J (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297: 681-683.
45. Muller AA (2004). New drugs of abuse update: Foxy Methoxy. J Emerg Nurs 30: 507-508.
46. Njung'e K, Handley SL (1991). Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38: 63-67.
47. O'Callaghan JP, Miller DB (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Therap 270: 741-751.
48. O'Callaghan JP, Miller DB (2002). Neurotoxic effects of substituted amphetamines in mice and rats: Challenges to the current dogma. In: Massaro EJ (ed). Handbook of Neurotoxicity. Humana Press: Totowa, NJ. pp. 269-301.
49. O'Dell SJ, Marshall JF (2002). Effects of vibrissae removal on methamphetamine-induced damage to rat somatosensory cortical neurons. Synapse 43: 122-130.
50. Rowland NE, Carlton J (1986). Neurobiology of an anorectic drug: Fenfluramine. Prog Neurobiol 27: 13-62.
51. Rowland NE, Kalehua AN, Li B-H, Semple-Rowland SL, Streit WJ (1993). Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions. Brain Res 624: 35-43.
52. Schmued LC (2003). Demonstration and localization of neuronal degeneration in the rat forebrain following a single exposure to MDMA. Brain Res 974: 127-133.
53. Schmued L, Slikker W, Clausing P, Bowyer J (1999). d-Fenfluramine produces neuronal degeneration in localized regions of the cortex, thalamus, and cerebellum of the rat. Toxicol Sci 48: 100-106.
54. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J (2004). Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav 29: 743-752.
55. Schroder N, O'Dell SJ, Marshall JF (2003). Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse 49: 89-96.
56. Selye H (1936). A syndrome produced by diverse nocuous agents. Nature 138: 32.
57. Shulgin AT, Carter MF (1980). N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun Psychopharmacol 4: 363-369.
58. Skelton MR, Blankenmeyer TL, Gudelsky GA, Brown-Strittholt CA, Vorhees CV, Williams MT (2004). Metyrapone attenuates the sequential learning deficits but not monoamine depletions following d,l-fenfluramine administration to adult rats. Synapse 54: 214-222.
59. Smolinske SC, Rastogi R, Schenkel S (2004). Foxy methoxy: a new drug of abuse. Internet J Med Toxicol 7: 3.
60. Stewart CW, Slikker Jr W (1999). Hyperthermia-enhanced serotonin (5-HT) depletion resulting from D-fenfluramine (D-Fen) exposure does not evoke a glial-cell response in the central nervous system of rats. Brain Res 839: 279-282.
61. Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K (2006). A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic Sci Int 163: 152-154.
62. US Drug Enforcement Administration (2003). Notice of intent to place alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Microgram Bull 36: 41-43.
63. Vorhees CV (1987). Maze learning in rats: a comparison of performance in two water mazes in progeny prenatally exposed to different doses of phenytoin. Neurotoxicol Teratol 9: 235-241.
64. Wallace TL, Gudelsky GA, Vorhees CV (1999). Methamphetamineinduced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci 19: 9141-9148.
65. West GB, Woodruff WH, Brown JH (2002). Allometric scaling of metabolic rate from molecules and mitochondria to cells and mammals. Proc Natl Acad Sci USA 99(Suppl 1): 2473-2478.
66. White CR, Seymour RS (2005). Sample size and mass range effects on the allometric exponent of basal metabolic rate. Comp Biochem Physiol A Mol Integr Physiol 142: 74-78.
67. Williams MT, Moran MS, Vorhees CV (2003a). Refining the critical period for methamphetamine-induced spatial deficits in the Morris water maze. Psychopharmacology 168: 329-338.
68. Williams MT, Morford LL, McCrea AE, Inman-Wood SL, Vorhees CV (2001). Elevations in plasmatic titers of corticosterone and aldosterone, in the absence of changes in ACTH, testosterone, or glial fibrillary acidic protein, 72 h following d,l-fenfluramine or d-fenfluramine administration to rats. Neurotoxicol Teratol 23: 23-32.
69. Williams MT, Morford LL, McCrea AE, Wood SL, Vorhees CV (2002). Administration of d,l-fenfluramine to rats produces learning deficits in the Cincinnati water maze but not the Morris water maze: relationship to adrenal cortical output. Neurotoxicol Teratol 24: 783-796.
70. Williams MT, Morford LL, Wood SL, Wallace TL, Fukumura M, Broening HW et al (2003b). Developmental d-methamphetamine treatment selectively induces spatial navigation impairments in reference memory in the Morris water maze while sparing working memory. Synapse 48: 138-148.
71. Wilson JM, McGeorge F, Smolinske S, Meatherall R (2005). A foxy intoxication. Forensic Sci Int 148: 31-36.